Author:
Cerchione Claudio,Catalano Lucio,Pareto Anna Emanuele,Picardi Marco,Pane Fabrizio
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228–237
2. Pettengell R, Schwenkglenks M, Leonard R et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299–1309
3. United States Department of Health & Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Published: May 28, 2009 (v4.03: June 14, 2010)
4. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205
5. National Comprehensive Cancer Network (NCCN), Inc. Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 1.2012. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive . Accessed 1 Aug 2012
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献